Customer support

xie@china-sinoway.com
English
banner
Products
Home

API

Tofacitinib Citrate 540737-29-9

Tofacitinib Citrate 540737-29-9

99% up, Medical Grade
  • Product Details

Product Information


Product name

Tofacitinib Citrate

CAS No.

540737-29-9

Molecular Formula

C16H20N6O.C6H8O7

Molecular Weight

504.5

Quality Standard

99% up, Medicine Grade

Appearance

White powder


COA of Tofacitinib Citrate


Item

Specification

Result

Appearance

White crystalline powder

Complies

Related substance (HPLC)

Total impurity ≤0.5%

Max single impurity ≤0.1%

0.2%

0.06%

Odor

Characteristic

Complies

Assay

99%

99.8%

Sieve analysis

100% pass 80 mesh

Complies

Loss on Drying

Residue on Ignition

≤1.0%

≤1.0%

0.12%

0.09%

Heavy Metal

<10ppm

Complies

As

<0.1ppm

0.05ppm

Pb

<0.1ppm

0.05ppm

Cd

<0.1ppm

0.05ppm

Residual Solvents

<100ppm

Complies

Residual Pesticide

Negative

Complies

Microbiology

 

 

Total Plate Count

<1000cfu/g

Complies

Yeast & Mold

<100cfu/g

Complies

E.Coli

Negative

Complies

Salmonella

Negative

Complies

Conclusion

Conforms with In-house standards


Usage


Function of Tofacitinib Citrate

1. Rheumatoid arthritis (RA)

Tofacitinib citrate is a new class of anti-rheumatic drugs approved by the US FDA for the first time in ten years. Compared with other traditional anti-rheumatic drugs, it can not only relieve symptoms, but also slow or stop disease damage. Its clinical therapeutic effect is also comparable to biological drugs such as adalimumab. So far, monoclonal antibodies or fusion proteins are the main clinical treatments for RA, which require injections, and tofacitinib has greater advantages as an oral drug.


The results of clinical studies show that tofacitinib still has satisfactory clinical effects for RA patients whose treatment with biological agents is ineffective. Therefore, these studies have further established its therapeutic status in patients with moderate to severe RA.


2. Treatment of active psoriatic arthritis (PsA)

In May 2017, the US FDA accepted the supplementary new drug application of Xeljanz and Xeljanz XR for the treatment of adult patients with active psoriatic arthritis (PsA).


The new drug supplement application is based on data from the Phase III clinical development project OPAL. The project includes two pivotal Phase III clinical studies (OPAL Broaden, OPAL Beyond) and a long-term extension study (OPAL Balance), which evaluated the use of tofacitinib in adult patients with active PsA who have previously failed PsA drug therapy. Efficacy and safety.


3. Treat ulcerative colitis (UC)

In May 2017, in the New England Journal of Medicine, the small molecule JAK inhibitor tofacitinib developed by Pfizer in the treatment of ulcerative colitis (UC) in three phase III clinical trials proved that it is in moderate to severe In UC patients, the treatment of tofacitinib is effective, and the efficacy of many patients can last for more than a year.


4. Treatment of ankylosing spondylitis (AS)

Ankylosing spondylitis (AS) is an immune-mediated chronic systemic inflammatory disease that affects the spine. Phase II clinical studies have confirmed the efficacy and safety of tofacitinib in the treatment of active AS.


Clinical trial showed that nearly 30% of patients with AS who received tofacitinib can achieve a clinically significant reduction in MRI inflammation of the spine; compared with patients in the placebo group, the sacroiliac of the tofacitinib group The joint scores and spine scores both improved and were dose-related; the proportion of patients in the tofacitinib group that achieved MCID of the sacroiliac joint or spine was 4 times that of the placebo group; the clinical response rate of patients in the tofacitinib group who achieved MCID higher.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Mupirocin powder
MUPIROCIN 12650-69-0
99% up / GMP
IMATINIB MESYLATE
IMATINIB MESYLATE 220127-57-1
In-house Standard
CEFTIOFUR SODIUM
CEFTIOFUR SODIUM 104010-37-9
In-house Specification
OSELTAMIVIR PHOSPHATE
OSELTAMIVIR PHOSPHATE 204255-11-8
99% up , Pharmaceutical Grade
THYMOPENTIN
THYMOPENTIN 69558-55-0
99% up Medical Grade
LOSARTAN POTASSIUM
LOSARTAN POTASSIUM 124750-99-8
98.5% up, USP32 
AZILSARTAN
AZILSARTAN 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact